Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. P. Velosa, W. Teodoro, M. R. Callado, A. Santos Filho, S. Fernezlian, M. L. Katayama, P. Martin, E. Parra, N. Yoshinari, V. L. Capelozzi (Brazil). Collagen V nasal tolerance promotes decrease in topoisomerase-1 and pulmonary fibrosis of systemic sclerosis model. Eur Respir J 2010; 36: Suppl. 54, 4219

Member's Comments

No comment yet.

Related content which might interest you: Type V collagen nasal tolerance regulates collagen mRNA synthesis in pulmonary remodeling of experimental systemic sclerosis Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Collagen V and decorin is involved in systemic sclerosis pulmonary fibrosis Source: Annual Congress 2011 - The ageing pulmonary interstitium Year: 2011 Increased mRNA expression of collagen V gene in pulmonary fibrosis of systemic sclerosis Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009 Abnormal collagen type V deposition in lung fibroblast is correlated with a worse pulmonary function in systemic sclerosis Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases Year: 2007 Pulmonary interstitium remodeling by collagen V is associated with profibrotic cytocines in experimental systemic sclerosis Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases Year: 2007 Collagen V nasal tolerance reverts pulmonary immune cells proliferation and interstitium remodeling in experimental scleroderma Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases Year: 2007 Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1393-1402 Year: 2015 Refractory remodeling of intrapulmonary arteries by type V collagen, apoptosis and endothelial activation in experimental systemic sclerosis Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Systemic sclerosis patients‘ sera recognize collagen V in experimental scleroderma lung fibrosis Source: Annual Congress 2011 - The ageing pulmonary interstitium Year: 2011 Treg alterations lead to systemic and local immune deregulation in idiopathic pulmonary fibrosis and collagen vascular disease-associated interstitial pneumonia Source: Annual Congress 2007 - Cell biology of asthma and COPD Year: 2007 Nintedanib inhibits fibroblast activation and ameliorates pulmonary and dermal fibrosis in models of systemic sclerosis (SSc) Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Expression of hyaluronidase by interstitial myofibroblasts and epithelial cells is associated with fibrosis extension, clinical forms and pulmonary function stage in patients with systemic sclerosis Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010 Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003 Increased endothelial and epithelial apoptosis play a central role in the pathogenesis of systemic sclerosis and idiopathic pulmonary fibrosis Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Systemic autoimmunity and  pulmonary fibrosis Source: International Congress 2017 – GR3 Scientific Grand Round: Autoimmunity in chronic lung disease Year: 2017 Up-regulation of collagen type V mRNA in a model of systemic sclerosis Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011 Transcription factor FOXp3 is over expressed in BALT of systemic sclerosis model induced by collagen V nasal tolerance Source: Annual Congress 2011 - Animal models of airway inflammation Year: 2011 Nintedanib inhibits contractile activity of lung myofibroblasts in a cellular model of scleroderma associated pulmonary fibrosis Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Auto-antibody subsets and extent of pulmonary fibrosis in systemic sclerosis (SSc) Source: Eur Respir J 2005; 26: Suppl. 49, 202s Year: 2005 17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice Source: International Congress 2016 – ILD pathogenesis Year: 2016